Health News Releases

  • Today May 16
March 03, 2020 16:04
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion re
March 03, 2020 16:00
PDC*line Pharma Announces the Administration of a First Patient With Its Therapeutic Cancer Vaccine Candidate (PDC*lung01) Targeting Non-small Cell Lung Cancer
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative
March 03, 2020 15:21
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin Americ
March 02, 2020 13:44
Coronavirus IS a Pandemic — WHO, Declare It Now!
Since AIDS Healthcare Foundation (AHF) released a statement this past Tuesday calling for World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus to declare the novel coronavirus (CO
March 02, 2020 10:08
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketin
March 02, 2020 10:06
Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommend
February 28, 2020 10:25
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) pl
The Success of ReSound Technology Is Amplified and Multiplied for Even More People With Hearing Loss
February 27, 2020 17:34
The Success of ReSound Technology Is Amplified and Multiplied for Even More People With Hearing Loss
GN Hearing, the innovation leader in hearing aid technology, today launches a range of exciting new ReSound hearing aid solutions, a move which is in line with the company’s continuous strategic focus
February 27, 2020 11:40
Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that it has acquired PvP Biologics, Inc. following the conclusion of a Phase 1 proof-of-mechanism study of investigationa
February 26, 2020 11:49
Masimo and MS Westfalia GmbH (MSW) Expand Partnership to Add Masimo SedLine® Brain Function Monitoring, O3® Regional Oximetry, and Oxygen Reserve Index (ORi™) to the MSW Modular Point-of-Care Hybrid Jenny
Masimo (NASDAQ: MASI) and MS Westfalia GmbH (MSW) announced today that MSW will integrate additional Masimo measurement technologies into MSW’s plug-and-play hybrid Jenny platform, to help clinicians
February 25, 2020 16:45
Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s supplemental New Drug Applicati
February 25, 2020 14:37
Bioventus Recognizes 25 Years of Proven Bone Healing from EXOGEN
Bioventus, a global leader in orthobiologic solutions, is recognizing 25 years of proven bone healing with its EXOGEN Ultrasound Bone Healing System. EXOGEN uses low-intensity pulsed ultrasound (LIPUS
February 25, 2020 13:29
Arima Genomics Completes Series A Financing
Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has complete
February 25, 2020 13:07
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary
February 20, 2020 17:50
Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis
Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from m
February 20, 2020 10:55
Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced the
February 19, 2020 10:26
Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox
Boehringer Ingelheim and Carebox Healthcare Solutions announced the recent launch of MyStudyWindow (www.mystudywindow.com), a digital platform empowering patients, families, caregivers, and doctors to
February 17, 2020 13:35
Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutan
February 17, 2020 13:10
Octapharma Group Delivered Strong Growth in Both Sales and Operating Income In 2019
Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “Octapharma delivered an exceptionally strong result in 2019. We achieved good growth in all three of our therap
Siemens Ltd. Seoul appoints Thomas Schmid as New Head of Digital Industries
February 17, 2020 09:41
Siemens Ltd. Seoul appoints Thomas Schmid as New Head of Digital Industries
A global powerhouse in electrical engineering and electronics leading the age of digitalization, Siemens Ltd. Seoul (SLS) announced the appointment of Mr. Thomas Schmid as Head of the company’s Digita
February 13, 2020 13:11
Sonion Announces Niels Svenningsen as New CEO & President
Sonion today announces the appointment of Niels Svenningsen as CEO & President of the Sonion Group. Niels Svenningsen was most recently President of Northern Europe in Schneider Electric and brings a
February 13, 2020 10:11
CARMELINA® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes
Boehringer Ingelheim have announced the results of a subgroup analysis of the CARMELINA® trial which demonstrate that linagliptin did not increase the risk of adverse cardiovascular events or hypoglyc
February 12, 2020 19:21
PCI Pharma Services Announces the Acquisition of Bellwyck Pharma Services to Expand Global Clinical Trial Services into Canada and Continental Europe
PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, today announced the acquisition of Bellwyck Pharma Services (Bellwyck), headquartered
February 12, 2020 17:48
SpeeDx Pty. Ltd. Raises Additional $15 million in Series B Funding
SpeeDx Pty Ltd, the developer of innovative clinical diagnostics to support improved patient outcomes, today announced it has raised $15 million in additional series B equity investment from U.S.-base
February 11, 2020 09:58
OncoSec Announces Closing of the CGP/Sirtex Transaction
OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that, following shareholder approval, the
25 per page50 per page75 per page100 per page